Hepatotoxicity observed in clinical trials of aplaviroc (GW873140)

被引:130
作者
Nichols, W. G. [1 ]
Steel, H. M. [1 ]
Bonny, T. [1 ]
Adkison, K. [1 ]
Curtis, L. [1 ]
Millard, J. [1 ]
Kabeya, K. [2 ]
Clumeck, N. [2 ]
机构
[1] GlaxoSmithKline Inc, Res Triangle Pk, NC 27709 USA
[2] CHU St Pierre, Brussels, Belgium
关键词
D O I
10.1128/AAC.00821-07
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
Aplaviroc (APL) was a new CCR5 antagonist that was investigated in two dose-ranging studies with antiretroviral therapy-naive, human immunodeficiency virus-infected adults: ASCENT, in which 147 subjects were randomized 2:2:1 to receive zidovudine-lamivudine (ZDV-3TC) plus APL 600 mg twice a day (BID), APL 800 mg BID, or efavirenz (EFV), respectively, and EPIC, in which 195 subjects were randomized 2:2:2:1 to receive lopinavir-ritonavir (LPV-RTV) plus APL 200 mg BID, APL 400 mg BID, APL 800 mg once a day, or ZDV-3TC BID, respectively. Both studies (and, ultimately, the clinical development of APL) were discontinued after a mean of 14 weeks of therapy because of higher than anticipated severe liver toxicity; grade 2 or higher treatment-emergent elevations in alanine aminotransferase (ALT) levels were observed in 17/281 (6.0%) APL recipients but only 2/55 (3.6%) control recipients, while grade 2 or higher elevations in total bilirubin levels occurred in 29/281 (10.3%) APL recipients but only 4155 (7.3%) controls. Two APL recipients developed grade 3 or higher treatment-emergent elevations in both ALT and total bilirubin levels, and one of these individuals had a severe case of hepatic cytolysis that was attributed to APL. Despite the high intersubject variability in APL plasma exposures, a Pearson correlation analysis of the combined study data did not reveal any significant associations between plasma concentrations and the liver enzyme elevations observed during the study. The mechanism for the idiosyncratic hepatotoxicity observed in the clinical trials of APL is unknown but is likely intrinsic to the molecule rather than its novel mechanism of action.
引用
收藏
页码:858 / 865
页数:8
相关论文
共 25 条
[1]   The effects of ritonavir and lopinavir/ritonavir on the pharmacokinetics of a novel CCR5 antagonist, aplaviroc, in healthy subjects [J].
Adkison, Kimberly K. ;
Shachoy-Clark, Anne ;
Fang, Lei ;
Lou, Yu ;
Otto, Vicky R. ;
Berrey, M. Michelle ;
Piscitelli, Stephen C. .
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2006, 62 (03) :336-344
[2]   Pharmacokinetics and short-term safety of 873140, a novel CCR5 antagonist, in healthy adult subjects [J].
Adkison, KK ;
Shachoy-Clark, A ;
Fang, L ;
Lou, Y ;
O'Mara, K ;
Berrey, MM ;
Piscitelli, SC .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2005, 49 (07) :2802-2806
[3]   Lack of chemokine receptor CCR5 promotes murine fulminant liver failure by preventing the apoptosis of activated CD1d-restricted NKT cells [J].
Ajuebor, MN ;
Aspinall, AI ;
Zhou, F ;
Le, T ;
Yang, Y ;
Urbanski, SJ ;
Sidobre, W ;
Kronenberg, M ;
Hogaboam, CM ;
Swain, MG .
JOURNAL OF IMMUNOLOGY, 2005, 174 (12) :8027-8037
[4]   Drug-induced liver injury:: An analysis of 461 incidences submitted to the Spanish Registry over a 10-year period [J].
Andrade, RJ ;
Lucena, MI ;
Fernández, MC ;
Pelaez, G ;
Pachkoria, K ;
García-Ruiz, E ;
García-Munoz, B ;
González-Grande, R ;
Pizarro, A ;
Durán, JA ;
Jiménez, M ;
Rodrigo, L ;
Romero-Gomez, M ;
Navarro, JM ;
Planas, R ;
Costa, J ;
Borras, A ;
Soler, A ;
Salmerón, J ;
Martin-Vivaldi, R .
GASTROENTEROLOGY, 2005, 129 (02) :512-521
[5]   Hepatotoxicity in drug development: Detection, significance and solutions [J].
Ballet, F .
JOURNAL OF HEPATOLOGY, 1997, 26 :26-36
[6]   Outcome and prognostic markers in severe drug-induced liver disease [J].
Björnsson, E ;
Olsson, R .
HEPATOLOGY, 2005, 42 (02) :481-489
[7]  
CURRIER J, 2006, 8 INT C DRUG THER HI
[8]  
FDA Working Group, 2000, CDER PHRMAAASLD C 20
[9]  
FRY J, 2007, FDA FCHR COLL PUBL M
[10]   Novel HIV treatment approved [J].
Groeschen, Heather M. ;
Provost, George P. .
AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY, 2007, 64 (18) :1886-1886